share_log

4: Statement of changes in beneficial ownership of securities-Officer Bligh James

4: Statement of changes in beneficial ownership of securities-Officer Bligh James

4:持股变动声明-高管 Bligh James
美股SEC公告 ·  2024/11/20 16:33

Moomoo AI 已提取核心信息

Interim CFO of Conduit Pharmaceuticals, Bligh James, has engaged in a transaction involving the company's stock on November 18, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Bligh James, but without further information, the impact on his total number of shares held after the action cannot be determined.
Interim CFO of Conduit Pharmaceuticals, Bligh James, has engaged in a transaction involving the company's stock on November 18, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Bligh James, but without further information, the impact on his total number of shares held after the action cannot be determined.
Conduit Pharmaceuticals的临时首席财务官Bligh James在2024年11月18日进行了与公司股票相关的交易。公告中未披露交易的具体细节,包括股票数量、股票性质、交易价格和股票总价值。此举反映了Bligh James的持股变动,但没有进一步的信息,无法确定此举对他在行动后持有的股票总数的影响。
Conduit Pharmaceuticals的临时首席财务官Bligh James在2024年11月18日进行了与公司股票相关的交易。公告中未披露交易的具体细节,包括股票数量、股票性质、交易价格和股票总价值。此举反映了Bligh James的持股变动,但没有进一步的信息,无法确定此举对他在行动后持有的股票总数的影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息